PubMed Health⌕ Search

Biomedical subjects

A F Woodhour

Publications and source records attributed to A F Woodhour.

At least 19 recordsLinked to original sources
PubMed1987

Haemophilus influenzae type b polysaccharide-protein conjugate vaccine.

An Haemophilus influenzae type b capsular polysaccharide-protein conjugate has been prepared. The polysaccharide was coupled to the serotype II protein of group B meningococcus through the spacer 6-aminocaproic acid using cyanogen bromide and water soluble carbodiimide. The conjugate can be shown to be reproducible and is stable and highly immunogenic in mice and African green monkeys. Clinical evaluation of this conjugate in children 3 months to 4 years of age showed that it elicited an antibody titer to the polysaccharide moiety greater than 1000 ng/ml in children 8 months of age or older.

Animals↗
PubMed1979

Enzyme-linked immunosorbent assay for measurement of antibodies against pneumococcal polysaccharide antigens: comparison with radioimmunoassay.

An enzyme-linked immunosorbent assay (ELISA) for measuring antibodies against each of 14 polysaccharides in contemporary pneumococcal vaccine is described, and the findings of tests of paired sera from vaccinated human subjects are compared with those obtained by radioimmunoassay. The findings were in very poor agreement, and this appears to be due to the lesser ability of the ELISA procedure to measure antibody of low avidity. The ELISA procedure described here is not considered to be a satisfactory substitute for radioimmunoassay for measuring antibody responses to pneumococcal vaccine.

Antibodies, Bacterial↗
PubMed1978

Polyvalent pneumococcal polysaccharide vaccines.

A 14-valent pneumococcal vaccine has recently been licensed for general use after extensive testing in human subjects. Antibody production was satisfactory in 92% of individuals and a highly significant (76-92%) reduction was found in the rates for pneumococcal pneumonias caused by the capsular types present in the vaccine. Children over 2 years of age respond well to the vaccine, but younger children may not respond satisfactorily to some capsular types. In adults, the duration of the protective effect is at present unknown, but no substantial booster response was seen after a second dose at 1 year. Such a booster dose, in fact, induced a marked increase in the degree of local reaction at the injection site.

Antibodies, Bacterial↗